Profile
John Fry worked at Alios BioPharma, Inc. from 2011 to 2018, where he held the position of VP-Head-Early Development & Infectious Diseases from 2014 to 2018.
He then joined Aligos Therapeutics, Inc. in 2018 and worked there until 2023 as the Executive Vice President-Clinical Development.
Prior to his professional career, Mr. Fry completed his undergraduate degree at the University of Sussex.
Former positions of John Fry
Companies | Position | End |
---|---|---|
ALIGOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/03/2023 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 31/10/2014 |
Training of John Fry
University of Sussex | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ALIGOS THERAPEUTICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- John Fry